What is StemCyte International, Ltd.'s (4178.TW) StockRank?

MoatMap's StockRank for StemCyte International, Ltd. (4178.TW) is 12/100, with a Strong Sell signal. This is a composite score combining Quality (43), Value (30), and Momentum (19) factor ranks across MoatMap's 20,000+ stock universe.

Does StemCyte International, Ltd. have an economic moat?

StemCyte International, Ltd. (4178.TW) has a Quality factor score of 43/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is StemCyte International, Ltd. a buy, hold, or sell?

MoatMap's current signal for StemCyte International, Ltd. (4178.TW) is Strong Sell, based on a StockRank of 12/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is StemCyte International, Ltd. in?

StemCyte International, Ltd. (4178.TW) operates in the Healthcare sector, specifically the Biotechnology industry (Taiwan).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

4178.TW

STRONG SELLREMOVE

StemCyte International, Ltd. · Healthcare · Taiwan · $117M · Avg Vol: $234K/d

StockRank

P/E (TTM)

—

ROE

-9.9%

D/E

0.1x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

StemCyte is a speculative stem cell therapy and cord blood banking firm. It lacks the scale, regulatory moat, and cash flow of established CDMO leaders.

COMPANY DESCRIPTION

StemCyte International, Ltd. is a biotechnology company specializing in cord blood banking, stem cell processing, and the development of cellular therapies. The company possesses a highly diverse, dual-accredited global cord blood registry used in clinical transplants worldwide. It is an international leader in stem cell therapeutics, integrating private banking services with clinical-stage therapeutic pipelines.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	11.0M	11.5M	12.1M	11.7M	2.0%
EPS	-0.01	-0.07	-0.04	—	—
Shares	192.1M	192.1M	190.5M	192.5M	+0.2%
Debt	1.3M	1.9M	7.9M	6.9M	74.3%
Equity	11.2M	26.4M	61.6M	54.9M	69.8%
Op CF	-1.1M	-2.9M	-4.5M	-1.7M	—
Inv CF	-2.6M	-3.3M	-6.9M	-3.4M	—
Fin CF	-1.0M	24.9M	37.1M	-0.3M	—

PRICE (1Y)-12.1%

SMA 50SMA 200

$0.53

RSI (14)

19.7

52W High

$1.07

From 52W High

0.5%

SCORE BREAKDOWN

Quality

ROIC

-5.6%38.4

ROE

-9.9%35.2

GP/Assets

3.8%16.9

Op. Margin

-63.9%19.3

FCF/Assets

-0.7%48.0

Piotroski

549.0

Int. Cover

-12.0x21.5

D/E Ratio

0.13x62.1

Current Ratio

10.80x88.1

Value

P/E (TTM)

—N/A

EV/EBITDA

-7.5x25.0

P/FCF

—N/A

P/B

2.0x58.9

P/S

10.5x25.5

Div Yield

—N/A

Momentum

52W High %

49%26.6

RS 6M

-100%9.3

SMA 50/200

0.82x17.8

EPS Rev 4W

-0.5%28.7

EPS Rev 12W

—N/A

EPS Improve

—16.2

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$117M

P/E (Forward)

-16.8x

Gross Margin

32.4%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 4178.TW are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
4178.TW	StemCyte International, Ltd.(you)	$117M	12	STRONG SELL
6838.TW	Formosa Pharmaceuticals, Inc.	$116M	15	STRONG SELL
6733.TWO	BioGend Therapeutics Co., Ltd.	$102M	12	STRONG SELL
6492.TWO	Senhwa Biosciences, Inc.	$121M	17	STRONG SELL
6657.TW	Energenesis Biomedical CO.,LTD.	$101M	8	STRONG SELL
6885.TW	BRIM Biotechnology, Inc.	$91M	9	STRONG SELL
MENS	Jyong Biotech Ltd.	$121M	4	STRONG SELL
4168.TWO	GlycoNex Incorporation	$91M	17	STRONG SELL
4174.TWO	OBI Pharma, Inc.	$116M	1	STRONG SELL
6461.TWO	Intech Biopharm Corporation	$84M	6	STRONG SELL

Peer medians: ROE 3.6% · P/E 16.2x · Gross margin 42.1%

StemCyte International, Ltd. (4178.TW) — Stock Score Summary

StemCyte International, Ltd. (4178.TW) has a MoatMap StockRank of 12/100 based on Quality (43/100), Value (30/100), and Momentum (19/100) factor scores. The current signal is STRONG SELL. StemCyte is a speculative stem cell therapy and cord blood banking firm. It lacks the scale, regulatory moat, and cash flow of established CDMO leaders.

Key Financial Metrics

Price	$0.53
Market Cap	$117M
P/E (Forward)	-16.83
Price/Book	2.00
Return on Equity	-9.9%
Return on Invested Capital	-5.6%
Debt/Equity	12.81
Gross Margin	32.4%
Operating Margin	-63.9%
Revenue Growth	-11.3%
Free Cash Flow	$-23K

StemCyte International, Ltd. operates in the Biotechnology industry, part of the Healthcare sector (Taiwan).

Frequently Asked Questions

What is StemCyte International, Ltd.’s (4178.TW) StockRank?: MoatMap’s StockRank for StemCyte International, Ltd. (4178.TW) is 12/100, with a Strong Sell signal. It is a composite of Quality (43), Value (30), and Momentum (19) factor ranks across MoatMap’s 20,000+ stock universe.
Does StemCyte International, Ltd. have an economic moat?: StemCyte International, Ltd. (4178.TW) has a Quality factor score of 43/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is StemCyte International, Ltd. a buy, hold, or sell?: MoatMap’s current signal for StemCyte International, Ltd. (4178.TW) is Strong Sell, based on a StockRank of 12/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is StemCyte International, Ltd. in?: StemCyte International, Ltd. (4178.TW) operates in the Healthcare sector, specifically the Biotechnology industry (Taiwan).